IP Library Granted Patent US 12,320,793
Granted Patent B2
US 12,320,793 · App. 18/360,292 · Granted Jun 3, 2025

Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient

Inventors: Takeshi Wakasugi (Osaka, JP); Aya Sano (Osaka, JP)
Assignee: MITSUBISHI TANABE PHARMA CORPORATION
G01N33/15A61K31/415A61K31/4152C07D231/26G01N30/06G01N2030/027G01N2030/042G01N2030/067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,320,793
App. No.
18/360,292
Granted
Jun 3, 2025
Kind
B2
Abstract

A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 μg/mL to 10 μg/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value. The first acidic water includes hydrochloric acid, the first water-soluble organic solvent is acetonitrile and/or methanol, the second acidic water includes hydrochloric acid, and the second water-soluble organic solvent is acetonitrile and/or methanol.

Claims (26)

1. A method of analyzing a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, comprising:

obtaining a first measured value by measuring a phenylhydrazine content in a phenylhydrazine standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration in a range of 0.01 μg/mL to 10 μg/mL;

obtaining a second measured value by measuring a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent; and

detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and the second measured value,

wherein the first acidic water includes hydrochloric acid and has an acid concentration in a range of 0.01 mol/L to 1 mol/L, the first water-soluble organic solvent is at least one selected from the group consisting of acetonitrile and methanol and has a volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution in a range of 9:1 to 6:1 such that the phenylhydrazine or a salt thereof is soluble in the phenylhydrazine standard solution, the second acidic water includes hydrochloric acid and has an acid concentration in a range of 0.01 mol/L to 1 mol/L, and the second water-soluble organic solvent is at least one selected from the group consisting of acetonitrile and methanol and has a volume ratio of the second acidic water and the second water-soluble organic solvent in the 3-methyl-1-phenyl-2-pyrazoline-5-one sample solution in a range of 9:1 to 6:1 such that the 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient is soluble in the 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution.

2. The method according to claim 1 , further comprising:

preparing the phenylhydrazine standard solution; and

preparing the 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution.

3. The method according to claim 1 , wherein the first measured value is obtained by measuring the phenylhydrazine content in the phenylhydrazine standard solution using high performance liquid chromatography, and the second measured value is obtained by measuring the phenylhydrazine content in the 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution using high performance liquid chromatography.

4. The method according to claim 1 , wherein the first water-soluble organic solvent includes methanol, and the second water-soluble organic solvent includes acetonitrile.

5. The method according to claim 1 , wherein the acid concentration of the first acidic water is 0.01 mol/L, and the acid concentration of the second acidic water is 0.01 mol/L.

6. The method according to claim 5 , wherein the first water-soluble organic solvent has the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution such that a symmetry coefficient for a peak of phenylhydrazine in high performance liquid chromatography is 0.9 or higher.

7. The method according to claim 2 , wherein the first measured value is obtained by measuring the phenylhydrazine content in the phenylhydrazine standard solution using high performance liquid chromatography, and the second measured value is obtained by measuring the phenylhydrazine content in the 3-methyl-1-phenyl-2-pyrazolin-5-one sample solution using high performance liquid chromatography.

8. The method according to claim 2 , wherein the first water-soluble organic solvent includes methanol, and the second water-soluble organic solvent includes acetonitrile.

9. The method according to claim 2 , wherein the acid concentration of the first acidic water is 0.01 mol/L, and the acid concentration of the second acidic water is 0.01 mol/L.

10. The method according to claim 9 , wherein the first water-soluble organic solvent has the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution such that a symmetry coefficient for a peak of phenylhydrazine in high performance liquid chromatography is 0.9 or higher.

11. The method according to claim 3 , wherein the first water-soluble organic solvent includes methanol, and the second water-soluble organic solvent includes acetonitrile.

12. The method according to claim 3 , wherein the acid concentration of the first acidic water is 0.01 mol/L, and the acid concentration of the second acidic water is 0.01 mol/L.

13. The method according to claim 12 , wherein the first water-soluble organic solvent has the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution such that a symmetry coefficient for a peak of phenylhydrazine in high performance liquid chromatography is 0.9 or higher.

14. The method according to claim 4 , wherein the acid concentration of the first acidic water is 0.01 mol/L, and the acid concentration of the second acidic water is 0.01 mol/L.

15. The method according to claim 14 , wherein the first water-soluble organic solvent has the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution such that a symmetry coefficient for a peak of phenylhydrazine in high performance liquid chromatography is 0.9 or higher.

16. The method according to claim 7 , wherein the first water-soluble organic solvent includes methanol, and the second water-soluble organic solvent includes acetonitrile.

17. The method according to claim 7 , wherein the acid concentration of the first acidic water is 0.01 mol/L, and the acid concentration of the second acidic water is 0.01 mol/L.

18. The method according to claim 17 , wherein the first water-soluble organic solvent has the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution such that a symmetry coefficient for a peak of phenylhydrazine in high performance liquid chromatography is 0.9 or higher.

19. The method according to claim 16 , wherein the acid concentration of the first acidic water is 0.01 mol/L, and the acid concentration of the second acidic water is 0.01 mol/L.

20. The method according to claim 19 , wherein the first water-soluble organic solvent has the volume ratio of the first acidic water and the first water-soluble organic solvent in the phenylhydrazine standard solution such that a symmetry coefficient for a peak of phenylhydrazine in high performance liquid chromatography is 0.9 or higher.

Assignments (3)
CHANGE OF NAME Recorded Apr 22, 2026
From: MITSUBISHI TANABE PHARMA CORPORATION
To: TANABE PHARMA CORPORATION
Reel/Frame 075454/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2026
From: TANABE PHARMA CORPORATION
To: SHIONOGI INC.
Reel/Frame 074428/0218 →
CHANGE OF NAME Recorded Mar 5, 2026
From: MITSUBISHI TANABE PHARMA CORPORATION
To: TANABE PHARMA CORPORATION
Reel/Frame 073977/0840 →
Priority Claims (1)
WO PCT/JP2018/007544 · Feb 28, 2018 · international
Continuity (4)
Continuation 17730853 · Apr 27, 2022
Division 17536947 · Nov 29, 2021
Continuation 16976287
Related Publication 20230366867A1 · Nov 16, 2023
References Cited (25)
US 4857542A · Nishi et al. · 1989 [cited by applicant]
US 7211596B2 · Yoshida et al. · 2007 [cited by applicant]
US 9956203B2 · Ozaki et al. · 2018 [cited by applicant]
US 10987341B2 · Hayama et al. · 2021 [cited by applicant]
US 11241416B2 · Hayama et al. · 2022 [cited by applicant]
US 11740219B2 · Wakasugi · 2023 [cited by examiner]
CN 102841170A · 2012 [cited by applicant]
CN 103454370A · 2013 [cited by applicant]
CN 106117144A · 2016 [cited by applicant]
JP S63132833A · 1988 [cited by applicant]
JP 05031523B2 · 1993 [cited by applicant]
JP 2008001606A · 2008 [cited by applicant]
JP 2008001607A · 2008 [cited by applicant]
JP 2010077104A · 2010 [cited by applicant]
WO WO02034264A1 · 2002 [cited by applicant]
WO WO2019031495A1 · 2019 [cited by applicant]
Li Shuai et al., “Optimization of HPLC determination of phenylhydrazine residues in edaravone” Central South Pharmacy, Aug. 2014, vol. 12 No. 8, pp. 814-816, with English translation. [cited by applicant]
International Search Report issued May 14, 2019 in PCT/JP2019/007415, filed Feb. 27, 2019, 2 pages. [cited by applicant]
International Preliminary Report on Patentability issued Sep. 1, 2020 in PCT/JP2019/007415, filed Feb. 27, 2019, 7 pages. [cited by applicant]
Extended European Search Report issued Oct. 28, 2021 in corresponding European Patent Application No. 19760101.6, 8 pages. [cited by applicant]
Tanaka et al. J. Clin. Biochem. Nutr., Nov. 2017, vol. 61, No. 3, pp. 164-168 (Published Online Oct. 26, 2017) (Year: 2017). [cited by applicant]
CN 103454370 Machine English Translation (Originally Published in Chinese on Dec. 18, 2013) (Machine Translated on Aug. 10, 2022: 7 pages) (Year: 2013). [cited by applicant]
Office Action issued Nov. 7, 2022, in corresponding Chinese Patent Application No. 201980015705.1, 16 pages. [cited by applicant]
“FDA approved edaravone for the treatment of patients with amyotrophic lateral sclerosis”, Chin J of Clinical Rational Drug Use, May 2017, vol. 10 No. 5B, p. 106 (with English Translation). [cited by applicant]
Office Action issued Mar. 22, 2023 in corresponding Japanese Patent Application No. 2020-503541 (with machine-generated English Translation), 15 pages. [cited by applicant]